Matthew Saybolt, MD
Interventional Cardiology · Eatontown, NJNPI 1841519709
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Abbott at 40.1% of the total. Among interventional cardiology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 831 payments — averaging $210.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$70K
- Medtronic$39K
- Shockwave Medical, Inc$31K
- Boston Scientific$23K
- Edwards Lifesciences$9K
- Abiomed$1K
- plus $2K from 30 others
Across 155 payments — averaging $3206.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$195K
- Boston Scientific$113K
- CSL Behring$95K
- Medtronic$42K
- Abbott$39K
- W. L. Gore & Associates, Inc.$12K
What the payments were for
- Consulting fees$76,26344%
- Speaking & faculty fees$39,40022%
- Travel & lodging$34,66720%
- Food & beverage$24,95014%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 292 | $70,235 |
| Medtronic(2 entities) | 111 | $38,983 |
| Shockwave Medical, Inc | 49 | $30,556 |
| Boston Scientific | 189 | $23,311 |
| Edwards Lifesciences | 76 | $8,703 |
| Abiomed | 18 | $1,007 |
| Heartflow, Inc. | 3 | $285 |
| E.r. Squibb & Sons, L.L.C. | 12 | $236 |
| Cardiovascular Systems Inc. | 4 | $202 |
| Alnylam Pharmaceuticals Inc. | 3 | $187 |
| Cathworks, Inc. | 2 | $181 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $174 |
| Kestra Medical Technology Services, Inc. | 3 | $157 |
| Novartis | 9 | $152 |
| Pfizer | 9 | $146 |
| Johnson & Johnson | 2 | $81 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $71 |
| Amgen | 4 | $68 |
| Boehringer Ingelheim | 4 | $61 |
| Portola Pharmaceuticals, LLC | 4 | $58 |
| Ancora Heart, Inc. | 2 | $43 |
| AstraZeneca | 3 | $41 |
| Cardinal Health 200 LLC | 2 | $38 |
| Bridgebio Pharma, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Chiesi USA, Inc. | 2 | $28 |
| Biotronik Inc. | 1 | $28 |
| Novo Nordisk | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Procyrion, Inc. | 1 | $21 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Cardiva Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$38,354
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$29,911
- RESOLUTE ONYX$9,497
- MitraClip$8,668
- GENERAL VASCULAR ACCESS$7,091
- COREVALVE EVOLUT R$4,023
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,943
- Dragonfly OCT$3,750
- Ultreon$3,082
- DRAGONFLY OPSTAR$2,938
- HI-TORQUE BALANCE$2,500
- AMPLATZER TALISMAN$2,000
- Perclose ProStyle$1,139
- Mitra Clip system$1,077
- GENERAL - THERAPIES$876
- AVVIGO Guidance System$587
- SYMPLICITY G3$560
- CoreValve Evolut$501
- ONYX FRONTIER$409
- EVOQUE$377
How this compares
$175,280 in reported general payments places this provider in the 95th percentile of 166 interventional cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 339 | $360,422 |
| VyndamaxTafamidis | 15 | $333,726 |
| XareltoRivaroxaban | 151 | $174,295 |
| EntrestoSacubitril/Valsartan | 117 | $149,948 |
| Repatha SureclickEvolocumab | 84 | $76,155 |
| FarxigaDapagliflozin Propanediol | 36 | $49,593 |
| JardianceEmpagliflozin | 34 | $46,348 |
| Praluent PenAlirocumab | 48 | $24,777 |
| NexletolBempedoic Acid | 18 | $7,874 |
| Metoprolol Succinate | 445 | $7,497 |
| Ezetimibe | 191 | $6,174 |
| Atorvastatin Calcium | 452 | $5,718 |
| Rosuvastatin Calcium | 371 | $5,620 |
| Valsartan | 102 | $3,972 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 11 | $3,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $146 | $694,148354 claims |
| Johnson & JohnsonXarelto | $81 | $174,295151 claims |
| NovartisEntresto | $152 | $149,948117 claims |
| AstraZenecaFarxiga | $41 | $49,59336 claims |
| Boehringer IngelheimJardiance | $61 | $46,34834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 interventional cardiology providers in New Jersey.
Other interventional cardiology in Eatontown
- Daniel KissEatontown$172K
- Isaac TawfikEatontown$23K
- David AnwarEatontown$12K
- Ankitkumar PatelGlen Ridge$408K
- Ziad AbbudOcean$360K
- Ramin HastingsHasbrouck Heights$295K
- Michael LimHackensack$215K
- Darshan GodkarCedar Knolls$194K
- Ryan KapleHackensack$178K
- Kintur SanghviBordentown$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.